ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer have?

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer has 590 citations in the OpenAlex counts ScholarIQ stores.

When was ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer published?

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer has 2015 year in the ScholarIQ index.

What is the open-access status of ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer?

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer has hybrid oa status in the ScholarIQ index.

What is the DOI of ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer?

The DOI for ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer is on the source record.

What is the PMID of ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer?

The PMID for ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer is on the source record.

What is the OpenAlex record for ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer?

The OpenAlex for ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer is on the source record.